A recent Phase III clinical trial has demonstrated that a biannual injection of lenacapavir lowers the risk of HIV infection by 96%. In the study, 99% of participants who received lenacapavir did not contract HIV. While approved for use in the U.S. and EU, lenacapavir is currently only available under specific circumstances. Experts emphasize the need for lower pricing to enable broader access and impact on global HIV infection rates. The cost is around €37,870, and Gilead is negotiating with manufacturers for a cheaper generic version in low-income countries.